Daewoong Pharmaceutical Co., Ltd (069620.KS)

112,100.00 -600.00 (-0.53%) As of 02:08PM KST. Market open.

Daewoong Pharmaceutical Co., Ltd

12, Bongeunsa-ro 114-gil
Gangnam-gu
Seoul 135-715
South Korea
82 2 550 8209
https://www.daewoong.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Seongsoo Park	CEO & Executive Director	N/A	N/A	1976
Mr. Chang-Jae Lee	CEO & Executive Director	N/A	N/A	1977
Eunkyeong Park	Executive Director	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Corporate Governance

Daewoong Pharmaceutical Co., Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.